Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S6.31
P/E—
Fwd P/E26.58
PEG1.29
52W— – —
RSI—
Target$94.12 (+13.4%)
Beta1.42
Div—
Loading chart…
RSI ()
Loading patterns…
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 40
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
6Bullish
5Bearish
0Neutral
Key Signals 1
▲ Double Bottom
Major reversal
2026-07-31 · $79.15
Two lows ~$68.55 — bullish reversal confirmed
Learn more →
Momentum Signals 10
▲ MACD Bullish Crossover
▲ Bull Flag
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
75%
6/8 quarters
Wall Street Consensus
STRONG BUY
BuyHoldSell
Price Target Range
$94.12
+13.4% upside
Low $79
—
High $115
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
62.47%Last 12 Months
Operating Margin
24.33%Last 12 Months
Return on Equity
38.49%Last 12 Months
Revenue Growth
13.10%Year over Year
Free Cash Flow
1.02BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
53.35Most Recent Quarter
Current Ratio
1.73Most Recent Quarter
Cash
1.95BMost Recent Quarter
Total Debt
1.40BMost Recent Quarter
Net Debt
—Most Recent Quarter
How DXCM Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 31.33B |
| Enterprise Value | 30.78B |
| Trailing P/E | 33.48 |
| Forward P/E | 26.58 |
| PEG Ratio (5yr) | 1.29 |
| Price/Sales (ttm) | 6.31 |
| Price/Book (mrq) | 11.95 |
| EV/Revenue | 6.20 |
| EV/EBITDA | 21.94 |
Share Statistics
| Avg Vol (3m) | 4.74M |
| Shares Outstanding | 377.36M |
| Float | 375.98M |
| % Held by Insiders | 0.26% |
| % Held by Institutions | 106.42% |
| Short Ratio | 3.37 |
| Short % of Float | 5.39% |
Profitability
| Gross Margin | 62.47% |
| Operating Margin (ttm) | 24.33% |
| Profit Margin | 20.12% |
| Return on Assets (ttm) | 10.33% |
| Return on Equity (ttm) | 38.49% |
Income Statement
| Revenue (ttm) | 4.97B |
| Revenue Growth (yoy) | 13.10% |
| Gross Profit (ttm) | 3.10B |
| EBITDA | 1.40B |
| Net Income (ttm) | 999.70M |
| Diluted EPS (ttm) | 2.48 |
| EPS Growth (yoy) | 43.60% |
Balance Sheet
| Total Cash (mrq) | 1.95B |
| Total Debt (mrq) | 1.40B |
| Debt / Equity (mrq) | 53.35 |
| Current Ratio (mrq) | 1.73 |
| Book Value / Share | 6.95 |
| Operating CF (ttm) | 1.75B |
| Free Cash Flow (ttm) | 1.02B |
Trading & Dividends
| Beta (5Y) | 1.42 |
| 50-Day MA | 82.13 |
| 200-Day MA | 71.27 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
No dividend history available for DXCM.
Ownership Breakdown
Institutional 106.42%
Insider 0.26%
Short Interest
5.39% of float
Moderate
Institutional 13F Holdings
Famous investors who disclosed a position in DXCM in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|